论文部分内容阅读
目的探讨子癎前期患者血浆纤溶酶原激活物抑制物-1(PAI-1)的变化及其在胎盘组织中的表达与临床意义。方法天津市中心妇产科医院应用ELASA法,检测2003-04-01-2003-10-01住院的42例子癎前期和15例正常妊娠妇女血浆PAI-1水平,SP免疫组化法检测对应胎盘组织中PAI-1的表达情况。结果重度子癎前期组血浆PAI-1明显高于轻度子癎前期组和正常对照组(P<0·01和P<0·001);轻度子癎前期组血浆PAI-l与正常妊娠组比较,差异无统计学意义(P>0·05);PAI-1在子癎前期患者的胎盘中呈阳性表达,重度子癎前期高于轻度组和正常妊娠组,差异有统计学意义(P<0.05)。结论子癎前期患者血浆PAI-1升高,并随病情加重,提示其对病情监测、预防并发症发生、疗效监测有重要价值。
Objective To investigate the changes of plasma plasminogen activator inhibitor-1 (PAI-1) and its expression in placenta and its clinical significance in preeclampsia. Methods ELASA method was used to detect plasma levels of PAI-1 in 42 preeclampsia and 15 normal pregnant women from 2003-04-01-2003-10-01 in Tianjin Central Obstetrics and Gynecology Hospital, SP immunohistochemical method was used to detect the placenta PAI-1 expression in tissues. Results The plasma level of PAI-1 in the severe preeclampsia group was significantly higher than that in the mild preeclampsia group and the normal control group (P <0.01 or P <0.001) (P> 0.05). PAI-1 was positively expressed in the placenta of patients with preeclampsia, the pre-severe stage of preeclampsia was higher than that of the mild and normal pregnancy groups, the difference was statistically significant (P <0.05). Conclusions PAI-1 in patients with preeclampsia is elevated and aggravates with illness, suggesting that it has important value in monitoring disease, preventing complications and monitoring curative effect.